127 related articles for article (PubMed ID: 14585373)
1. Expression of osteoprotegerin mRNA and protein in murine megakaryocytes.
Chagraoui H; Sabri S; Capron C; Villeval JL; Vainchenker W; Wendling F
Exp Hematol; 2003 Nov; 31(11):1081-8. PubMed ID: 14585373
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells.
Takai H; Kanematsu M; Yano K; Tsuda E; Higashio K; Ikeda K; Watanabe K; Yamada Y
J Biol Chem; 1998 Oct; 273(42):27091-6. PubMed ID: 9765225
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects.
Thirunavukkarasu K; Miles RR; Halladay DL; Yang X; Galvin RJ; Chandrasekhar S; Martin TJ; Onyia JE
J Biol Chem; 2001 Sep; 276(39):36241-50. PubMed ID: 11451955
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Br J Haematol; 2004 Jul; 126(2):244-51. PubMed ID: 15238146
[TBL] [Abstract][Full Text] [Related]
6. PTH differentially regulates expression of RANKL and OPG.
Huang JC; Sakata T; Pfleger LL; Bencsik M; Halloran BP; Bikle DD; Nissenson RA
J Bone Miner Res; 2004 Feb; 19(2):235-44. PubMed ID: 14969393
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO.
Chagraoui H; Tulliez M; Smayra T; Komura E; Giraudier S; Yun T; Lassau N; Vainchenker W; Wendling F
Blood; 2003 Apr; 101(8):2983-9. PubMed ID: 12506018
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
9. The expression of osteoprotegerin and the receptor activator of nuclear factor kappa B ligand in human periodontal ligament cells cultured with and without 1alpha,25-dihydroxyvitamin D3.
Zhang D; Yang YQ; Li XT; Fu MK
Arch Oral Biol; 2004 Jan; 49(1):71-6. PubMed ID: 14693199
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
[TBL] [Abstract][Full Text] [Related]
11. Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG).
Wang JC; Hemavathy K; Charles W; Zhang H; Dua PK; Novetsky AD; Chang T; Wong C; Jabara M
Exp Hematol; 2004 Oct; 32(10):905-10. PubMed ID: 15504545
[TBL] [Abstract][Full Text] [Related]
12. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Bone; 2005 May; 36(5):812-9. PubMed ID: 15794927
[TBL] [Abstract][Full Text] [Related]
13. [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells].
Su X; Liao EY; Peng J; Wu XP
Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):800-3. PubMed ID: 14636471
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin is expressed in colon carcinoma cells.
Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B
Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
Lee SK; Lorenzo JA
Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
[TBL] [Abstract][Full Text] [Related]
16. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation.
Karst M; Gorny G; Galvin RJ; Oursler MJ
J Cell Physiol; 2004 Jul; 200(1):99-106. PubMed ID: 15137062
[TBL] [Abstract][Full Text] [Related]
17. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts.
Thomas GP; Baker SU; Eisman JA; Gardiner EM
J Endocrinol; 2001 Aug; 170(2):451-60. PubMed ID: 11479141
[TBL] [Abstract][Full Text] [Related]
18. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.
Gori F; Hofbauer LC; Dunstan CR; Spelsberg TC; Khosla S; Riggs BL
Endocrinology; 2000 Dec; 141(12):4768-76. PubMed ID: 11108292
[TBL] [Abstract][Full Text] [Related]
19. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
[TBL] [Abstract][Full Text] [Related]
20. RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing.
Wilson SE; Mohan RR; Netto M; Perez V; Possin D; Huang J; Kwon R; Alekseev A; Rodriguez-Perez JP
Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2201-11. PubMed ID: 15223796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
